Business Wire

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Share

Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30 minutes prior to their percutaneous coronary intervention (PCI) compared to patients who received LV unloading followed by immediate PCI. The data were presented today during the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston by Navin K. Kapur, MD, executive director of the Cardiovascular Center for Research and Innovation (CVCRI) at Tufts Medical Center and the principal investigator for the STEMI DTU pivotal randomized controlled trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220917005003/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The STEMI DTU pilot trial demonstrated for the first time that LV unloading using the Impella CP® heart pump with a 30-minute delay before reperfusion is safe and feasible. (Graphic: Business Wire)

The new analysis compared infarct size in 32 patients from the STEMI DTU pilot trial who met all inclusion and exclusion criteria. All patients experienced an anterior STEMI and completed one of two treatment protocols – LV unloading with Impella CP followed by immediate PCI (n=15) or LV unloading with Impella CP for 30 minutes prior to delayed PCI (n=17). Cardiac magnetic resonance (CMR) imaging performed three-to-five days after PCI was used to determine infarct size (IS) normalized to the area at risk (AAR). Results showed that the infarct size normalized to the area at risk was significantly lower in the delayed PCI group compared to the immediate PCI group (IS/AAR: 47±16 vs. 60±16, p=0.02), which translates to a 22% relative and 13% absolute reduction in IS/AAR.

“Results from this analysis are early, but promising, indicating that in STEMI patients, unloading the left ventricle with Impella CP for 30 minutes and delaying PCI could potentially help improve patient outcomes by reducing damage to the heart muscle and helping prevent heart failure,” said Dr. Kapur.

Myocardial damage can lead to heart failure. Every 5% increase in infarct size is associated with a 20% increase in relative hazard for all-cause mortality or hospitalization for heart failure within one year after a primary PCI (JACC, 2016). Coronary artery disease is the number one cause of death in the United States and 47% of women and 36% of men over the age of 45 will die within five years of their first heart attack (Circulation, 2019).

The STEMI DTU pilot study demonstrated for the first time that LV unloading using Impella CP with a 30-minute delay before reperfusion via PCI is feasible, safe and not associated with an increase in infarct size. The pilot study led to the STEMI DTU pivotal randomized controlled trial, which began in 2019 and is actively enrolling patients. The pivotal trial is testing the hypothesis that compared to PCI alone, LV unloading for 30 minutes prior to PCI can reduce myocardial damage and future heart failure-related events due to a heart attack.

ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella heart pumps are not FDA approved for use in STEMI patients without cardiogenic shock.

ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (Nasdaq: ABMD) is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit abiomed.com.

FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com

Investor Contact:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kiln Announces €17 Million in Funding to Expand Staking Offering28.11.2022 12:00:00 EET | Press release

Today, Kiln announced the close of an €17 million financing round to expand their market-leading staking infrastructure product range. Kiln, the leading enterprise-grade staking technology provider, with over $500 million1 of assets staked under management, received funding from Illuminate Financial with participation by a number of leading crypto investing groups including Consensys, GSR, Kraken Ventures, Leadblock Partners, Sparkle Ventures, XBTO and renewed participation from existing investors 3KVC, Blue Yard Capital, SV Angel and Alven among others. Kiln believes that the staking market is becoming institutionalized and must move beyond running validators to meet the growing customer need to spread risk. This means creating validator-agnostic APIs and services to enable multi-provider staking. This in turn enables digital assets to be staked wherever they are held, for wallets, custodians, and exchanges. As the industry evolves and the need to integrate multiple staking players pr

Dawex & IDSA Applaud the Publication by Gaia-X of the First Data Exchange Services Specification Document, Marking a New Milestone for Developing a Strong, Secure, Trustworthy and Sovereign European Data Economy28.11.2022 11:00:00 EET | Press release

Dawex, the leading technology company for data exchange, data marketplace and data hub, and the International Data Spaces Association (IDSA), defining a global standard for trustworthy data connectors, respectively Lead and co-Lead of the Gaia-X Data Exchange Services Working Group, today applaud the first publication of the Gaia-X Data Exchange Services document, and congratulate the Working Group members on their active contribution and for reaching this exceptional milestone. The Gaia-X Data Exchange Services Specification document defines the vocabulary for data exchange, sets the definition of data exchange services as well as conceptual & operational models, data exchange policies and ontologies for data exchange to deliver trust, interoperability, discoverability and traceability to the data economy. The publication by Gaia-X of the Data Exchange Services Specification document is resulting from an intensive collaboration between members of the Data Exchange Services Working Gro

Fundsmith Appoints FundRock for Distribution of Fundsmith SICAV28.11.2022 11:00:00 EET | Press release

FundRock Management Company, a leading European third-party UCITS Management Company (“ManCo”) and Alternative Investment Fund Manager (“AIFM”), announces the expansion of its relationship with leading fund management company Fundsmith LLP, to now include distribution services. FundRock enables clients to streamline their operations in a cost-effective manner by offering third-party ManCo and fund distribution services under one roof, complemented by a wide range of fund administration, middle office, banking, depositary and custody services delivered through parent company Apex Group. In addition to existing ManCo services, FundRock Distribution S.A. will now provide distribution services, enabling Fundsmith LLP to distribute its funds in the EU. FundRock’s established network of more than 200 experts in key jurisdictions including Luxembourg, the United Kingdom, Ireland, Netherlands, France, Italy, Switzerland, Germany, Abu Dhabi and Singapore delivers significant time, resource and

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients28.11.2022 09:00:00 EET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/ CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide. “We are thrilled about the marketing authorization of Ferinject®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL Vifor. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject® can make a meaningful difference in the treatment of

BLUETTI Is to Supercharge ISPO 202228.11.2022 05:27:00 EET | Press release

BLUETTI, a global leader in the clean energy storage industry, will present its new inventions at ISPO, the world's largest sports trade show, to be held in Munich, Germany, from November 28 to November 30, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005071/en/ (Graphic: Business Wire) This year's ISPO focuses on 'New Perspectives in Sports', with themes such as innovation and sustainability. “We believe our participation could bring fresh insights into outdoor and at-home sports. Our clean and reliable energy solutions will empower sports lovers’ green lifestyles,” James Ray, the spokesman, explained BLUETTI's attendance. BLUETTI has released its latest masterpieces, the AC500&B300S and EP600&B500. The AC500 follows the modular design of the AC300 and is substantially updated in capacity and capability. With a 5.000W output and 16 outlets, it can be used as a solid backup power source on the go or in the hous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom